论文部分内容阅读
目的：探讨吡喃阿霉素为主增强剂量ＴＣＯＰ方案，治疗非霍奇金淋巴瘤的临床完全缓解率和３ 年生存率及骨髓抑制和心脏毒性等情况。方法：对２２ 例非霍奇金淋巴瘤患者进行吡喃阿霉素为主增强剂量ＴＣＯＰ方案治疗及良好的支持治疗并长期、定期治疗及随访。结果：全组完全缓解率为８６４ ％ ；１ 年生存率为９５５ ％ ，３ 年生存率为７３１％ 。骨髓抑制及心脏毒性等毒副反应未见明显增加。结论：吡喃阿霉素为主增强剂量ＴＣＯＰ方案与传统ＣＨＯＰ方案相比在完全缓解率和３ 年生存率上有明显提高而其骨髓抑制及心脏毒性等毒副反应未见明显增加
OBJECTIVE: To investigate the effect of pirarubicin as the main dose-enhancing TCOP regimen in the treatment of non-Hodgkin’s lymphoma with complete clinical remission rate, 3-year survival rate, myelosuppression and cardiotoxicity. METHODS: Twenty-two patients with non-Hodgkin’s lymphoma were treated with pirarubicin as the main dose-enhancing TCOP regimen and good supportive therapy, and long-term, regular treatment and follow-up. Results: The complete remission rate was 86.4%; the 1-year survival rate was 95.5%, and the 3-year survival rate was 73.1%. There was no significant increase in adverse effects such as myelosuppression and cardiotoxicity. CONCLUSIONS: Compared with the traditional CHOP regimen, the pirarubicin-based main dose-enhanced TCOP regimen showed a significant increase in complete remission rate and 3-year survival rate, while no significant increase in adverse effects such as myelosuppression and cardiac toxicity were observed.